Ocular Therapeutix Inc. (NASDAQ:OCUL) and Orgenesis Inc. (NASDAQ:ORGS) are two firms in the Biotechnology that compete against each other. Below is a comparison of their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Ocular Therapeutix Inc.||2.14M||73.59||63.34M||-1.59||0.00|
Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Ocular Therapeutix Inc. and Orgenesis Inc.
Table 2 provides Ocular Therapeutix Inc. and Orgenesis Inc.’s return on assets, return on equity and net margins.
|Net Margins||Return on Equity||Return on Assets|
|Ocular Therapeutix Inc.||-2,959.81%||-133.7%||-81.6%|
Risk & Volatility
Ocular Therapeutix Inc.’s 1.87 beta indicates that its volatility is 87.00% more volatile than that of Standard and Poor’s 500. Orgenesis Inc. on the other hand, has 1.37 beta which makes it 37.00% more volatile compared to Standard and Poor’s 500.
Ocular Therapeutix Inc.’s Current Ratio and Quick Ratio are 4.3 and 4.3 respectively. The Current Ratio and Quick Ratio of its competitor Orgenesis Inc. are 1.8 and 1.7 respectively. Ocular Therapeutix Inc. therefore has a better chance of paying off short and long-term obligations compared to Orgenesis Inc.
The Ratings and Recommendations for Ocular Therapeutix Inc. and Orgenesis Inc. are featured in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Ocular Therapeutix Inc.||0||0||5||3.00|
Ocular Therapeutix Inc.’s upside potential currently stands at 280.43% and an $14 consensus price target.
Insider & Institutional Ownership
Roughly 53.6% of Ocular Therapeutix Inc. shares are held by institutional investors while 2.8% of Orgenesis Inc. are owned by institutional investors. 0.2% are Ocular Therapeutix Inc.’s share held by insiders. Insiders Competitively, held 26.45% of Orgenesis Inc. shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Ocular Therapeutix Inc.||-1.26%||24.6%||-16.78%||-27.43%||-14.52%||18.34%|
For the past year Ocular Therapeutix Inc. was more bullish than Orgenesis Inc.
Orgenesis Inc. beats on 7 of the 11 factors Ocular Therapeutix Inc.
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of ocular therapies using its Hydrogel technology. Its product pipeline candidates utilize its platform to provide differentiated drug delivery solutions that are designed to reduce the complexity and burden of current drop or injection regimens by creating sustained release one-time or several-month dosage forms. The companyÂ’s lead product candidate, DEXTENZA (dexamethasone insert) 0.4 mg for intracanalicular use has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. It is also developing OTX-TP (travoprost insert), which is in Phase 3 clinical development for glaucoma and ocular hypertension. In addition, the company is evaluating injectable drug delivery depots for back-of-the-eye diseases. Further, its commercial product includes the ReSure Sealant, which has been approved by the Food and Drug Administration (FDA) for ophthalmic use. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.
Orgenesis Inc., a biopharmaceutical company, develops trans-differentiation technologies in the field of cell therapy and regenerative medicine. The company's Contract Development and Manufacturing Organization segment specializes in cell therapy development for advanced medicinal products. This segment provides process and assay development services; and GMP contract manufacturing services. Its Cellular Therapy Business segment develops cell trans-differentiation technology induce shift in the developmental fate of cells from the liver and differentiating them into pancreatic beta cell-like insulin-producing cells for patients with diabetes. Orgenesis Inc. has a collaboration agreement with Biosequel LLC to carry out clinical trials and market its products in Russia, Belarus, and Kazakhstan. The company was formerly known as Business Outsourcing Services, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was founded in 2008 and is based in Germantown, Maryland.